Article
Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.
The pharmacogenomics journal - 1 Jan 2018
Bank S, Andersen P S, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino S Y, Brodersen J B, Rashid S, Rasmussen B K, Avlund S, Olesen T B, Hoffmann H J, Nexø B A, Sode J, Vogel U, Andersen V
Abstract excerpt
Anti-tumour necrosis factor-α (TNF-α) is used for treatment of severe cases of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). However, one-third of the patients do not respond to the treatment. A recent study indicated that genetically determined high activity of pro-inflammatory cytokines, including interleukin-1β (IL-1β), IL-6 and interferon gamma (IFN-γ), are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.